Time to access matters: Patient gains from faster CAR T-cell reimbursement in Europe

In a literature review, researchers examined differences in time to reimbursement for CAR T-cell therapy in different European countries and quantified potential benefits from faster access. They found that France, Germany, and Switzerland had the fastest time to reimbursement decisions, whereas Denmark, the Netherlands, and Ireland had the slowest. They estimated that 1,199 lives, 1,222 long-term survivorships, and 37,229 life years could potentially be gained by ensuring that time to access across the slowest countries was equivalent to that in the fastest ones.